Peters KE, et al. – The specialists undertook this work to examine the ability of plasma apolipoprotein (apo) A–IV (apoA4), apo C–III, CD5 antigen–like (CD5L), complement C1q subcomponent subunit B (C1QB), complement factor H–related protein 2, and insulin–like growth factor binding protein 3 (IBP3) to predict rapid decline in estimated glomerular filtration rate (eGFR) in type 2 diabetes. They suggested that novel plasma biomarkers (apoA4, CD5L, C1QB, and IBP3) might improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in type 2 diabetes.